What is the appropriate follow-up care for an older adult female presenting to an outpatient clinic after a pulmonary embolism (PE) and being treated with apixaban (Eliquis)?

Follow-Up Care After Pulmonary Embolism on Apixaban

Routinely re-evaluate this patient at 3-6 months after the acute PE to assess for persistent symptoms, determine anticoagulation duration, and screen for chronic thromboembolic complications 1.

Timing and Structure of Follow-Up

The 3-month follow-up visit is the critical checkpoint for all PE patients 1. This timing allows adequate recovery while enabling early detection of complications like chronic thromboembolic pulmonary hypertension (CTEPH), which typically manifests beyond 3 months post-PE 1, 2.

Key Components of the Follow-Up Visit

1. Symptom Assessment

Specifically evaluate for:

• Persistent dyspnea on exertion (most important red flag for CTEPH or post-PE syndrome)
• Exercise intolerance or reduced functional capacity
• Chest pain
• Quality of life impairment 1, 2

2. Anticoagulation Duration Decision

This is the most critical decision point at 3 months. The algorithm is straightforward:

Discontinue apixaban after 3 months if:

• First PE provoked by a major transient/reversible risk factor (surgery, trauma, immobilization, estrogen therapy) 1

Continue apixaban indefinitely if:

• Unprovoked PE (no identifiable trigger)
• Recurrent VTE (prior PE or DVT episode)
• Active cancer
• Persistent risk factors 1

For extended anticoagulation beyond 6 months: Consider reducing apixaban from 5 mg twice daily to 2.5 mg twice daily to reduce bleeding risk while maintaining VTE prevention 3, 4. The FDA label specifically supports this reduced dose for secondary prevention after completing at least 6 months of treatment 4.

3. Screening for CTEPH and Post-PE Syndrome

If the patient reports persistent dyspnea or exercise limitation at 3 months:

• Order ventilation/perfusion (V/Q) lung scan as the preferred screening test for CTEPH 1
• Consider echocardiography, NT-proBNP, and/or cardiopulmonary exercise testing 1, 2
• If V/Q scan shows mismatched perfusion defects beyond 3 months: Refer to a pulmonary hypertension/CTEPH expert center 1

The ESC guidelines are explicit that symptomatic patients with mismatched perfusion defects require specialized referral 1. Right heart catheterization for CTEPH confirmation should only be performed at specialized centers 2.

4. Ongoing Anticoagulation Monitoring

For patients continuing extended anticoagulation, reassess at regular intervals:

• Drug adherence and tolerance
• Renal function (apixaban is partially renally cleared)
• Hepatic function
• Bleeding risk assessment 1

Important caveat: Apixaban requires dose reduction to 2.5 mg twice daily if the patient has ≥2 of the following: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 4. This is particularly relevant for older adult females.

Common Pitfalls to Avoid

1. Do not routinely screen for thrombophilia unless it will change management (young patients, strong family history, recurrent unprovoked VTE) 5

2. Do not use warfarin instead of apixaban unless there are specific contraindications to DOACs (severe renal impairment with CrCl <15 mL/min, antiphospholipid antibody syndrome) 1

3. Do not miss the 3-month window for CTEPH screening in symptomatic patients—delayed diagnosis worsens outcomes 1, 2

4. Do not continue full-dose anticoagulation indefinitely without reassessing bleeding risk, especially in older adults 1

Special Considerations for Older Adult Females

Older women have higher bleeding risk on anticoagulation, making the reduced-dose apixaban strategy (2.5 mg twice daily) particularly attractive for extended secondary prevention after 6 months 3, 4. The evidence shows this lower dose maintains efficacy for preventing recurrent VTE while reducing bleeding complications 3.

Monitor for dose-reduction criteria specific to this population: age ≥80, low body weight, and renal function decline 4.